Last reviewed · How we verify
travoprost 0.004% (drug)
travoprost 0.004% (drug) is a Prostaglandin F analog Small molecule drug developed by University Hospital, Basel, Switzerland. It is currently FDA-approved for Open-angle glaucoma, Ocular hypertension.
Travoprost is a prostaglandin F analog that binds to the prostaglandin F (FP) receptor to increase uveoscleral outflow of aqueous humor, thereby reducing intraocular pressure.
Travoprost is a prostaglandin F analog that binds to the prostaglandin F (FP) receptor to increase uveoscleral outflow of aqueous humor, thereby reducing intraocular pressure. Used for Open-angle glaucoma, Ocular hypertension.
At a glance
| Generic name | travoprost 0.004% (drug) |
|---|---|
| Sponsor | University Hospital, Basel, Switzerland |
| Drug class | Prostaglandin F analog |
| Target | Prostaglandin F receptor (FP receptor) |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Travoprost mimics the action of prostaglandin F by activating FP receptors on the ciliary muscle bundle and trabecular meshwork. This activation enhances drainage of aqueous humor through the uveoscleral (unconventional) pathway, leading to decreased intraocular pressure. The drug is selective for the FP receptor and does not significantly activate other prostaglandin receptors.
Approved indications
- Open-angle glaucoma
- Ocular hypertension
Common side effects
- Conjunctival hyperemia
- Iris pigmentation increase
- Eyelash growth (hypertrichosis)
- Eye irritation/discomfort
- Periocular skin pigmentation
Key clinical trials
- Travoprost Ophthalmic Topical Cream for Open-angle Glaucoma or Ocular Hypertension (PHASE2)
- Travoprost 0.004% Versus Pilocarpine 1% in Patients With Chronic Angle Closure Glaucoma (CACG) (PHASE4)
- Azopt (Brinzolamide 1.0%) Plus Travatan (Travoprost 0.004%) in Treating Patients With Chronic Angle-Closure Glaucoma (CACG) (PHASE4)
- Subjects With Open-angle Glaucoma, Pseudoexfoliative Glaucoma, or Ocular Hypertension Naïve to Medical and Surgical Therapy, Treated With Two Trabecular Micro-bypass Stents (iStent Inject) or Travoprost (PHASE4)
- Two Trabecular Micro-bypass Stents & Postoperative Travoprost to Treat Glaucoma Subjects on Two Hypotensive Agents (PHASE4)
- Effect Of Topical Prostaglandin F2α Analogs,Fractional CO2 Laser, Excimer Laser Or Their Combination In Treatment Of Vitiligo (PHASE4)
- Comparison Between Latanoprost , Travoprost and Tafluprost in Reducing IOP Fluctuation in POAG Patients
- Safety and Tolerability of the Ophthalmic Solution PRO-179 Compared With Travatan® (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- travoprost 0.004% (drug) CI brief — competitive landscape report
- travoprost 0.004% (drug) updates RSS · CI watch RSS
- University Hospital, Basel, Switzerland portfolio CI
Frequently asked questions about travoprost 0.004% (drug)
What is travoprost 0.004% (drug)?
How does travoprost 0.004% (drug) work?
What is travoprost 0.004% (drug) used for?
Who makes travoprost 0.004% (drug)?
What drug class is travoprost 0.004% (drug) in?
What development phase is travoprost 0.004% (drug) in?
What are the side effects of travoprost 0.004% (drug)?
What does travoprost 0.004% (drug) target?
Related
- Drug class: All Prostaglandin F analog drugs
- Target: All drugs targeting Prostaglandin F receptor (FP receptor)
- Manufacturer: University Hospital, Basel, Switzerland — full pipeline
- Therapeutic area: All drugs in Ophthalmology
- Indication: Drugs for Open-angle glaucoma
- Indication: Drugs for Ocular hypertension
- Compare: travoprost 0.004% (drug) vs similar drugs
- Pricing: travoprost 0.004% (drug) cost, discount & access